Routine proteinuria monitoring for bevacizumab in patients with gynecologic malignancies.

Autor:	Lee CS; Department of Pharmacy, University of Washington Medical Center, Seattle, WA, USA cathlee@seattlecca.org., Alwan LM; Department of Pharmacy, University of Washington Medical Center, Seattle, WA, USA., Sun X, McLean KA; Division of Gynecologic Oncology, University of Washington Medical Center, Seattle, WA, USA., Urban RR; Division of Gynecologic Oncology, University of Washington Medical Center, Seattle, WA, USA.
Jazyk:	angličtina
Zdroj:	Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2016 Dec; Vol. 22 (6), pp. 771-776. Date of Electronic Publication: 2015 Oct 06.
DOI:	10.1177/1078155215609987
Abstrakt:	Background: Proteinuria leading to nephrotic syndrome is a rare adverse event arising from treatment with bevacizumab. There is limited evidence to guide the frequency and appropriate test for monitoring for proteinuria. The purpose of this study was to determine the prevalence and severity of proteinuria during bevacizumab administration to patients with gynecologic malignancies, and to evaluate risk factors associated with this toxicity; a secondary objective was to evaluate the cost of routine proteinuria monitoring to assess for opportunities of cost containment that could change clinical practice. Methods: A retrospective chart review was performed at an academic gynecologic oncology clinic. Women over 18 years of age with a diagnosed gynecologic malignancy were evaluated for the development of proteinuria while receiving bevacizumab treatment as measured by a urine protein-to-creatinine ratio. Patient and disease-specific risk factors were evaluated using logistic regression to determine correlations of risk factors to development of proteinuria. Cost assessment was performed using institution-specific data for urine laboratory tests. Results: Eighty-nine patients were identified, and the overall prevalence of proteinuria of any grade was 35%. The mean number of bevacizumab cycles was 13 (2-64 cycles). The majority of patients experienced grade 1 proteinuria (70%, 62 patients). Grade 3 proteinuria was observed in two patients (2%). There was a trend toward increased bevacizumab cycles associated with increased grade proteinuria (p = 0.053), however there were no factors significantly associated with the development of proteinuria as measured by urine protein-to-creatinine ratio. Conclusion: Monitoring of urine protein-to-creatinine ratios with each cycle may be unnecessary due to the low prevalence of grade 3 proteinuria observed. Additionally, urine protein-to-creatinine ratios may not provide adequate assessment of proteinuria toxicity associated with bevacizumab therapy. Potential cost savings opportunities for the institution can be realized with a cost-reductive monitoring algorithm that will utilize less costly laboratory techniques for patients at high risk of developing proteinuria. (© The Author(s) 2015.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu